Long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) may mitigate adherence challenges reported by young women in Southern Africa. We assessed preferences for PrEP in public-sector, primary care clinics in Swaziland. Among surveyed respondents, 75% (95% confidence interval U 65-83%) stated preference for LAI over oral PrEP; with no differences by sex, age, or sexual behavior (all P > 0.05). Notably, over 70% (95% confidence interval 58-82%) with current use of oral PrEP also stated preference for LAI PrEP.
Over 25% of new HIV infections in Southern Africa occur in women aged 15-24, who account for only 10% of the population, yet have HIV incidence rates as high as 8/100 person-years [1] . Consequently, effective interventions to prevent HIV infection in this demographic will have a considerable public health impact, and are a prerequisite to realizing global HIV prevention goals [2] .
Despite a diversifying toolbox of interventions, effective strategies to prevent HIV in young women in Southern Africa are lacking. Whereas oral formulations of preexposure prophylaxis (PrEP) are efficacious in MSM [3, 4] , injecting drug users [5] , and members of stable, discordant partnerships [6, 7] , similar evaluations among young women in Southern Africa have failed to demonstrate benefit in clinical trials [8, 9] . Women in these studies have described stigma and hindering social norms, which discouraged them from taking pills openly, and challenges adhering to therapy [10] [11] [12] . Thus, interventions that empower women to avoid daily, home-based dosing could perceivably help women overcome barriers to PrEP use.
The advent of long-acting injectable (LAI) PrEP has been proposed as a strategy to avert many of these barriers, in part, due to the precedent of LAI contraception in this population [13] . HPTN 084 (NCT03164564) is assessing the efficacy of LAI cabotegravir every 2 months versus daily oral PrEP in a randomized, double-blinded clinical trial. However, there are few data available about preferences for LAI PrEP, particularly in comparison to oral PrEP in Southern Africa. Acceptability data will be crucial ahead of implementation studies for LAI PrEP.
The Swaziland Ministry of Health, with support from Clinton Health Access Initiative, Swaziland, is conducting a PrEP demonstration project in six public-sector, primary-care clinics in Swaziland. PrEP is conceptually introduced to patients during daily general health education sessions. During the ensuing clinic visit, either a healthcare worker (HCW) or patient may initiate engagement for PrEP use. Data for this study were collected at exit interviews among those who engaged with a HCW, using a sampling approach described previously [14] . In addition to questions about sociodemographics, sexual behavior, and PrEP history, we elicited preferences for injectable versus oral PrEP with the following question:
Currently PrEP is only available in a tablet form, taking 1 tablet a day to reduce the risk of HIV infection. Scientists are working to make a different kind of HIV prevention medicine that would involve getting an injection in the muscle every 2 months. If in the future an injectable PrEP would become available, would you have a preference for either oral or injectable PrEP [15] ?
Responses to this question included: I would prefer injectable PrEP every 2 months; I would prefer oral PrEP taken daily; I would have no preference for either injectable or oral PrEP; or I am not interested in either injectable PrEP or daily oral PrEP. We tabulated responses to this question by sociodemographic, clinical, sexual, and oral PrEP history characteristics, and used chi-squared tests to assess for differences in oral versus LAI preferences. Study procedures were approved by the Swaziland Ministry of Health National Research Review Board and the Chesapeake Institutional Review Board, and all respondents gave oral consent to participate.
Of the 115 individuals who completed the questionnaire, 109 (95%) completed the PrEP preferences question, 2 (2%) expressed no preference for oral or LAI PrEP, and 107 (93%) stated a clear preference for oral or injectable PrEP, and were included in this analysis. Of the respondents, 86% (92/107) were female and had a median age of 28 years (interquartile range 22-35); with 36% (39/107) between 18 and 24 years of age. Seventy-five percentage of respondents [95% confidence interval (CI) ¼ 65-83%] expressed a preference for LAI every 2 months over daily oral PrEP. This preference was reported in both sexes (P ¼ 0.16), across educational attainment categories (P ¼ 0.12), and across the spectrum of age (P ¼ 0.78) (Supplementary Table 1 , http://links. lww.com/QAD/B285). There was also a preference for LAI PrEP irrespective of number of sexual partners in the past 12 months, condom use practices, or disclosure of PrEP use to partners. Notably, we found that most women currently or previously using PrEP also stated a preference for LAI over oral PrEP (Fig. 1) . Older women (>35) were nominally more likely to prefer LAI to oral PrEP than those less than 25 (89% versus 72%; P ¼ 0.32).
In summary, approximately three in four individuals engaging in PrEP services in outpatient care in Swaziland reported a preference for LAI over oral PrEP for prevention of HIV, and this preference was consistent across demographic and sexual behavior characteristics. Moreover, those starting PrEP on the day of the interview and those who had experienced PrEP in the past were particularly in favor of LAI. Our data are cross-sectional, include a relatively small sample size that is not powered to show small to moderate differences between subgroups, and are drawn from a population that only has access to oral PrEP. Consequently, our data do not consider the challenges of LAI in practice, such as discomfort with injections or frequency of visits to the clinic.
Our results, however, are in keeping with prior work. A mixed-methods study conducted during the HPTN 076 study, in which young HIV-negative women received injectable rilpivirine for PrEP, also suggested that women had a preference for LAI over oral PrEP [16] . Interestingly, the level of stated desirability in that study and ours appears similar to or slightly higher than the rates reported in MSM in the United States, among whom approximately 50-80% have stated a preference for LAI [15, 17, 18] . Our findings suggest a potential for LAI PrEP for HIV prevention among women in the Southern African region, a population that has been historically difficult to reach with effective PrEP services. Consequently, as LAI PrEP efficacy data among young women in Southern Africa become available, an important next step will entail conducting demonstration studies to assess the real-world feasibility and effectiveness of LAI agents for HIV PrEP. PrEP: HIV pre-exposure prophylaxis
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Proportion Preferring Long-Acting Injectable PrEP over Oral PrEP Fig. 1 . Proportion of women completing a public-sector ambulatory visit in Swaziland who report a preference for long-acting injectable PrEP over once-daily oral PrEP for HIV prevention. PrEP, HIV pre-exposure prophylaxis.
